Empagliflozin (Jardiance) is being studied in three parallel Phase 2 trials across Germany, Switzerland, and the US — including a critical question: can it be safely combined with tolvaptan?
Background
While dapagliflozin is testing the SGLT2 class in a large Phase 3, empagliflozin trials are answering different questions: Is it safe to combine with tolvaptan (which also affects water balance)? What happens to kidney oxygenation? Can it reduce the polyuria burden from tolvaptan? Three independent investigator-initiated trials are running simultaneously.
How It Works
Empagliflozin, like dapagliflozin, blocks SGLT2 in the kidney proximal tubule. The key question being addressed is pharmacological interaction with tolvaptan (vasopressin receptor antagonist). Both drugs affect renal water handling: tolvaptan blocks water reabsorption in collecting ducts (causing massive urine output), while SGLT2 inhibitors cause osmotic diuresis through glucose excretion. The combination could be synergistic (both slow cysts) or problematic (excessive dehydration).
Clinical Trial Details
Three trials are running: EMPA-PKD (NCT06391450, Hannover, n=44) testing empagliflozin + tolvaptan combination safety; SIDIA (NCT06435858, Zurich, n=40) measuring kidney oxygenation with MRI; and a Colorado Feasibility study (NCT05510115, n=50) testing tolerability. Combined enrollment across all three is approximately 134 patients.
Why It's Promising
If the combination with tolvaptan proves safe, it opens the door to dual therapy — attacking PKD through both vasopressin blockade and SGLT2 inhibition simultaneously. This could significantly improve outcomes beyond either drug alone.
Limitations & Concerns
Small pilot studies — none are powered for efficacy endpoints. Risk of dehydration and electrolyte imbalances with the combination. Results from these trials will inform larger studies but won't prove efficacy on their own.